Winston-Salem, North Carolina ,United States, March 2026 — Masimo has welcomed Dr. Sam Ajizian as Vice President, Medical Affairs. With a background spanning pediatric critical care and executive medical leadership, Dr. Ajizian brings deep expertise at the intersection of clinical practice, patient safety, and medical technology innovation.
In this role at Masimo, Dr. Sam Ajizian will support medical affairs priorities aligned with the company’s mission to improve life, improve patient outcomes, reduce the cost of care, and expand noninvasive monitoring to new sites and applications. His appointment strengthens Masimo’s clinical leadership as the company continues advancing monitoring technologies, connectivity, and automation solutions across care settings.
Prior to joining Masimo, Dr. Ajizian served as Chief Medical Officer at Inflammatix, Inc., contributing to clinical strategy and medical leadership responsibilities within a diagnostics-focused environment.
Earlier, he served as Chief Medical Officer of Medtronic’s Acute Care & Monitoring operating unit, holding global medical leadership responsibility in a role focused on clinical strategy and innovation within acute and monitoring care.
Before that, he spent multiple years with Medtronic in senior clinical leadership roles, including serving as VP, Clinical Research & Medical Science for Respiratory Interventions & Patient Monitoring and as Chief Medical Officer, Patient Monitoring, supporting clinical research, medical science, and strategy aligned to patient monitoring portfolios. He also served as Vice President, Medical Safety, strengthening governance and patient safety leadership within complex healthcare technology environments.
Alongside his industry leadership experience, Dr. Ajizian has a long-standing clinical and academic foundation, having served as Associate Professor of Anesthesiology, Pediatric Critical Care at Wake Forest School of Medicine for more than a decade, and working as an academic pediatric intensivist at Brenner Children’s Hospital.
He holds a Doctor of Medicine (MD) from the University of Southern California and a Bachelor of Arts (BA) in Animal Physiology from UC San Diego, reflecting a strong medical and scientific foundation supporting his leadership journey.
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Masimo’s mission is to improve life, improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications.
Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent studies. Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World’s Best Hospitals listing.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
Click Here to Join HR TODAY WhatsApp Channel









